Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | GNRHR | P30968 | 1/20 | 0.32 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.31 |
| ▸ | FYN | P06241 | 1/20 | 0.31 |
| ▸ | KDR | P35968 | 2/20 | 0.30 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.30 |
| ▸ | AURKA | O14965 | 1/20 | 0.30 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.30 |
| ▸ | INSR | P06213 | 1/20 | 0.30 |
| ▸ | FBP1 | P09467 | 1/20 | 0.30 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.30 |
| ▸ | FLT4 | P35916 | 1/20 | 0.30 |
| ▸ | CLK1 | P49759 | 1/20 | 0.30 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10300247 | 0.87 | EGFR (0.36) | NPC1GNRHREGFRMAPTKDR | |
| SCHEMBL10300232 | 0.86 | EGFR (0.36) | NPC1EGFRMAPTKDRERBB2 | |
| SCHEMBL3109749 | 0.84 | LMNA (0.40) | NPC1MEN1KMT2APKMGNRHR | |
| SCHEMBL1744643 | 0.81 | NPC1 (0.47) | NPC1 | |
| SCHEMBL3100037 | 0.80 | NPC1 (0.44) | NPC1MEN1KMT2AGNRHRCACNA1C | |
| SCHEMBL3094203 | 0.80 | NPC1 (0.38) | NPC1MEN1KMT2AGNRHRCACNA1C | |
| Hydrochloric Acid SCHEMBL3094626 | 0.79 | NPC1 (0.43) | NPC1MEN1KMT2AGNRHRCACNA1C | |
| SCHEMBL10300237 | 0.77 | NPC1 (0.41) | NPC1MEN1KMT2APKMGNRHR | |
| SCHEMBL3106513 | 0.76 | NPC1 (0.40) | NPC1MEN1KMT2AGNRHRCACNA1C | |
| SCHEMBL13577266 | 0.76 | NPC1 (0.41) | NPC1MEN1KMT2AGNRHRCACNA1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2143724-B1 | NITROGENATED FUSED RING DERIVATIVE, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, AND USE OF THE SAME FOR MEDICAL PURPOSES | KISSEI PHARMACEUTICAL (JP) | 2013-12-11 | — | — | EP | disclosed |
| US-8217069-B2 | Nitrogenated fused ring derivative, pharmaceutical composition comprising the same, and use of the same for medical purposes | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-07-10 | — | — | US | disclosed |
| US-20100112090-A1 | NITROGENATED FUSED RING DERIVATIVE, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, AND USE OF THE SAME FOR MEDICAL PURPOSES | KISSEI PHARMACEUTICAL CO., LTD (JP) | 2010-05-06 | — | — | US | disclosed |
| EP-2143724-A1 | NITROGENATED FUSED RING DERIVATIVE, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, AND USE OF THE SAME FOR MEDICAL PURPOSES | Kissei Pharmaceutical Co., Ltd. (JP) | 2010-01-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100112090-A1 | NITROGENATED FUSED RING DERIVATIVE, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, AND USE OF THE SAME FOR MEDICAL PURPOSES | NR5A1, SHBG, GNRHR | NPC1 3052/4885MEN1 1726/4885KMT2A 2609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.